Filing Flows › Sunshine Biopharma (SBFM) › Q1 2025
Sunshine Biopharma (SBFM) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 15, 2025
Sunshine Biopharma (SBFM) reported revenue of $8.9M for the first quarter 2025 (Q1 2025), +18% from a year earlier and -7% from the quarter before. Operating margin was -14.6%, net loss $1.2M (13.3% of revenue).
Sunshine Biopharma, Q1 2025: revenue $8.9M (+18% year over year), operating margin -14.6%, net loss $1.2M, operating cash flow −$1.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.9M | -7% | +18% |
| Operating profit | −$1.3M | — | — |
| Net earnings | −$1.2M | — | — |
| Operating cash flow | −$1.7M | — | — |
What changed
Revenue was $8.9M in Q1 2025, up 18% year over year and down 7% from the previous quarter.
Gross margin was 30.7%, down 0.5 points from a year earlier. Operating costs exceeded revenue by $1.3M, an operating margin of -14.6%. Operating expenses grew 9% against revenue growth of 18%. The quarter ended with a net loss of $1.2M, narrower than the previous quarter's $2.2M loss.
Operating cash flow was −$1.7M. Non-cash charges added back $65K of depreciation. Working capital and other items used $580K. Capital expenditures of $7K exceeded it, leaving free cash flow of −$1.7M.
Questions
What was Sunshine Biopharma's revenue in the first quarter 2025?
Sunshine Biopharma (SBFM) reported revenue of $8.9M for the first quarter 2025 (Q1 2025), +18% from a year earlier and -7% from the quarter before.
Was Sunshine Biopharma profitable in the first quarter 2025?
Operating loss was $1.3M (-14.6% of revenue) and net loss $1.2M.
Source: Sunshine Biopharma 10-Q on SEC EDGAR.